← All trials
NCT05536726
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 31, 2022
- Primary completion
- Jun 30, 2024
- Completion date
- Sep 30, 2024
- First posted
- Sep 13, 2022
- Last posted
- Oct 19, 2022
- Enrollment
- 450
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Sunshine Lake Pharma Co., Ltd.Lead sponsor
- Sunshine Lake Pharma Co., Ltd.Study director
- Fudan UniversityOverall official - principal investigator
- Fudan UniversityOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.